Loading quotes...
Forecast
| Buy |
3 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
Oxford Nanopore Technologies falls after sale of 49 million shares by Novo Holdings
The stock of Oxford Nanopore Technologies fell 6.5% to 162.08 pence after Novo Holdings sold 49 million shares (~5% of the issued share capital) at 152 pence each (proceeds around £74m). The placement price was 12.3% below the previous closing price. The sell-off follows half-year results showing double-digit revenue growth but weaknesses in key regions, and comes amid higher yields and geopolitical uncertainty that are weighing on growth, valuation-sensitive stocks. » More on de.investing.com
Oxford Nanopore: CEO Francis Van Parys receives 49,676 ordinary shares from LTIP
Oxford Nanopore announced that CEO Francis Van Parys has received 49,676 new ordinary shares from the Long‑Term Incentive Plan 2021. The allocation followed vesting of awards granted in March 2026 and served as compensation for bonus commitments waived at his previous employer. The shares, with a nominal value of £0.0001 each, were issued on the London Stock Exchange and were granted to the director free of charge. » More on de.investing.com
Oxford Nanopore boosts margins and halves adjusted EBITDA loss; shares jump 16%
Oxford Nanopore reported H1 2026 revenue of £116.7m (FX‑adjusted +12.3%) but missed expectations due to weakness in China and the Middle East. Gross margin rose to 62.2% (+400 basis points) and the adjusted EBITDA loss narrowed from £48.3m to £22.1m, driven by higher device sales (+32.6%) and cost discipline. Management reiterated full‑year targets (FX‑adjusted revenue growth 16–20%, gross margin ~62%) and is targeting adjusted EBITDA break‑even in 2027 and positive free cash flow in 2028. Investors rewarded the margin improvement and turnaround plan with a pre‑market share gain of around 16%. » More on de.investing.com
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 134.49M | - |
| Gross profit | 83.67M | - |
| Net profit | -55.32M | - |
| EBITDA | -25.35M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €2.43B |
Number of shares | 980.9M |
52-week high/low | €2.85 - €1.14 |
| Dividends | No |
Beta | 0.91 |
P/E ratio | -16.31 |
PEG ratio | -1.22 |
P/B ratio | 4.68 |
P/S ratio | 8.55 |
Company profile
Oxford Nanopore Technologies plc develops and commercializes a technology platform using nanopore-based sensing for the analysis of various types of molecules. The company offers MinION, a portable device for deoxyribonucleic acid and ribonucleic acid sequencing; GridION, a self-contained benchtop device for running and analyzing up to five MinION or Flongle flow cells; MinION Mk1C for basecalling and data analysis, touchscreen operation, and wireless connectivity; Flongle, an adapter for use in MinION or GridION devices to attach a Flongle flow cell; GridION Mk1, a benchtop nanopore sequencer; PromethION 2 Solo and PromethION 2, a low-cost access to high-yield PromethION sequencing; PromethION 24 and PromethION 48 benchtop nanopore-based sequencers for multiple users to deliver multi-sample and multi-experiment sequencing results; and VolTRAX, an USB-powered device, which automates laboratory processes upstream of nanopore sequencing. It also provides MinKNOW, a software that offers data acquisition, real-time analysis and feedback, local basecalling, and data streaming; Basecalling tools to determine the identity and order of bases on the DNA/RNA molecule; EPI2ME, a cloud-based data analysis platform for end-to-end analysis of nanopore data in real time; and EPI2ME Labs, a bioinformatics solution to assist users in developing their skills and confidence in the analysis of their nanopore-based sequencing data. In addition, the company is developing MinION Mk1D; Ubi; Plongle; and SmidgION products. It sells its products online. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies Limited in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is based in Oxford, the United Kingdom.
| Name | OXFORD NANOPORE |
| CEO | Francis Albert Luc Van Parys |
| Headquarters | Oxford,
oxf United Kingdom |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 09/30/2021 |
| Employees | 1,403 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Pnk | ONTTF |
London Stock Exchange | ONT.L |
Frankfurt | 4R0.F |
Düsseldorf | 4R0.DU |
London | ONT.L |
München | 4R0.MU |